{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:19Z","timestamp":1792979899908,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Maribavir and valganciclovir are pharmacotherapeutic options utilized in the management of cytomegalovirus (CMV) infection post-transplantation. Despite their established utility, a comprehensive assessment of their safety profiles in real-world settings remains lacking, particularly with regards to long-term safety outcomes within a sizable cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The study aims to analyze the adverse event (AE) profiles of maribavir and valganciclovir using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). This endeavor seeks to juxtapose their respective association strengths and furnish clinicians with pertinent clinical reference points.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Employing a methodological framework involving the filtration of the FAERS database by specific drugs (maribavir and valganciclovir), AEs attributed to each agent were meticulously cataloged. We applied various disproportionation analysis techniques, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN) and multi-item gamma Poisson shrinker (MGPS) algorithms, to identify and quantify potential signals of AEs associated with maribavir and valganciclovir.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 999 and 3,454 reports for maribavir and valganciclovir, respectively. Maribavir was primarily associated with the following AEs: dysgeusia (133, 4.07%), taste disorder (127, 3.89%), death (120, 3.67%), fatigue (105, 3.21%), and diarrhea (69, 2.11%). In contrast, the most notable AEs linked to valganciclovir included death (260, 2.59%) and neutropenia (246, 2.59%), leukopenia (175, 1.74%), diarrhea (117, 1.17%), and thrombocytopenia (113, 1.13%). Remarkably, death emerged as an unexpected AE signature for both agents. Key associations were elucidated, notably taste disorder (ROR: 65.23) for maribavir and CMV colitis (ROR: 152.26) for valganciclovir, accentuating distinct AE propensities. Additionally, median onset times for AE manifestation were delineated, with maribavir exhibiting a median onset time of 40\u00a0days, compared to 28\u00a0days for valganciclovir-associated AEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This comprehensive analysis of FAERS data enhances our understanding of the safety. These findings hold implications for ongoing clinical surveillance efforts and provide a foundational basis for subsequent investigations into the safety profiles of these agents.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1518258","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T05:16:43Z","timestamp":1748236603000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system"],"prefix":"10.3389","volume":"16","author":[{"given":"Haolin","family":"Teng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102188","DOI":"10.1016\/j.trim.2025.102188","article-title":"CMV management of patients with leukopenia after CMV high-risk kidney transplantation","volume":"89","author":"Abu-Omar","year":"2025","journal-title":"Transpl. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","article-title":"Bayesian confidence propagation neural network","volume":"30","author":"Bate","year":"2007","journal-title":"Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1513\/AnnalsATS.202102-108OC","article-title":"A phase I randomized, controlled, clinical trial of valganciclovir in idiopathic pulmonary fibrosis","volume":"18","author":"Blackwell","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2024.11.026","article-title":"Maribavir for refractory cytomegalovirus infection (with or without resistance) in solid organ transplant recipients: subgroup analysis of the phase 3 randomized SOLSTICE study","author":"Blumberg","year":"2024","journal-title":"J. heart lung Transplant"},{"key":"B6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1053\/j.ajkd.2011.04.010","article-title":"Human cytomegalovirus and kidney transplantation: a clinician's update","volume":"58","author":"De Keyzer","year":"2011","journal-title":"Am. J. kidney Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. drug Saf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/MOT.0000000000001139","article-title":"Recent advances in cytomegalovirus infection management in solid organ transplant recipients","volume":"29","author":"Grossi","year":"2024","journal-title":"Curr. Opin. organ Transplant."},{"key":"B9","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/infdis\/jiz454","article-title":"Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence","volume":"221","author":"Haidar","year":"2020","journal-title":"J. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e00178","DOI":"10.1097\/BS9.0000000000000178","article-title":"Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation","volume":"6","author":"Li","year":"2024","journal-title":"Blood Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"Jama"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e19765","DOI":"10.1097\/MD.0000000000019765","article-title":"Efficacy and safety of valganciclovir in patients with symptomatic congenital cytomegalovirus disease: study Protocol Clinical Trial (SPIRIT Compliant)","volume":"99","author":"Morioka","year":"2020","journal-title":"Medicine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3390\/v16121889","article-title":"Real-world Comparison of maribavir to foscarnet for the treatment of cytomegalovirus in solid organ and hematopoietic stem cell transplant recipients","volume":"16","author":"Ogawa","year":"2024","journal-title":"Viruses"},{"key":"B15","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.esmoop.2021.100315","article-title":"Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"6","author":"Omar","year":"2021","journal-title":"ESMO open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/cid\/ciad709","article-title":"Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the aurora trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir","volume":"78","author":"Papanicolaou","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am. J. Transplant."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.cmi.2023.03.020","article-title":"Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients","volume":"29","author":"Razonable","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-guidelines of the American society of transplantation infectious diseases community of practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin. Transplant."},{"key":"B21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40360-025-00867-6","article-title":"Risk of drug-induced pericardial effusion: a disproportionality analysis of the FAERS database","volume":"26","author":"Ren","year":"2025","journal-title":"BMC Pharmacol. and Toxicol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/ckj\/sfx145","article-title":"High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation","volume":"11","author":"Rissling","year":"2018","journal-title":"Clin. kidney J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1523-1755.2004.00735.x","article-title":"Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival","volume":"66","author":"Sagedal","year":"2004","journal-title":"Kidney Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jiac.2016.05.006","article-title":"An overview of infectious complications after allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Sahin","year":"2016","journal-title":"J. Infect. Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Shu","year":"","journal-title":"Front. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"","journal-title":"Clin. Epidemiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jcph.2155","article-title":"Maribavir pharmacokinetics and safety in participants with moderate hepatic impairment: a phase 1, open-label, single-dose, parallel group study","volume":"63","author":"Song","year":"2023","journal-title":"J. Clin. Pharmacol."},{"key":"B28","first-page":"2116","article-title":"Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis","volume":"89","author":"Steinhart","year":"1994","journal-title":"Am. J. gastroenterology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/(SICI)1520-6017(200006)89:6<781::AID-JPS10>3.0.CO;2-7","article-title":"Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2","volume":"89","author":"Sugawara","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e13696","DOI":"10.1111\/cts.13696","article-title":"Maribavir: mechanism of action, clinical, and translational science","volume":"17","author":"Sun","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"851246","DOI":"10.3389\/fphar.2022.851246","article-title":"Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib","volume":"12","author":"Yin","year":"2022","journal-title":"Sci. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1333662","DOI":"10.3389\/fphar.2024.1333662","article-title":"A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","article-title":"A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"Zhao","year":"2023","journal-title":"Expert Opin. drug metabolism and Toxicol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1393940","DOI":"10.3389\/fphar.2024.1393940","article-title":"Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1518258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T05:16:44Z","timestamp":1748236604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1518258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":36,"alternative-id":["10.3389\/fphar.2025.1518258"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1518258","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"article-number":"1518258"}}